Bionano Genomics (NASDAQ:BNGO) Lowered to “Neutral” Rating by LADENBURG THALM/SH SH

LADENBURG THALM/SH SH lowered shares of Bionano Genomics (NASDAQ:BNGO) from a buy rating to a neutral rating in a research report sent to investors on Friday, MarketBeat reports.

BNGO has been the topic of several other reports. Scotiabank reissued a “sector perform” rating and issued a $1.00 target price (down from $6.00) on shares of Bionano Genomics in a research report on Wednesday, August 28th. BTIG Research downgraded shares of Bionano Genomics from a “buy” rating to a “neutral” rating in a report on Tuesday, September 10th.

Bionano Genomics Price Performance

Shares of NASDAQ BNGO opened at $0.25 on Friday. Bionano Genomics has a fifty-two week low of $0.24 and a fifty-two week high of $2.27. The company has a market cap of $21.16 million, a PE ratio of -0.11 and a beta of 2.37. The company has a debt-to-equity ratio of 0.04, a quick ratio of 1.11 and a current ratio of 1.63. The business has a 50-day simple moving average of $0.36 and a two-hundred day simple moving average of $0.59.

Institutional Investors Weigh In On Bionano Genomics

Institutional investors have recently bought and sold shares of the company. Virtu Financial LLC acquired a new stake in shares of Bionano Genomics in the first quarter valued at about $36,000. Carret Asset Management LLC lifted its position in Bionano Genomics by 89.0% in the third quarter. Carret Asset Management LLC now owns 85,055 shares of the company’s stock valued at $39,000 after buying an additional 40,055 shares during the last quarter. GSA Capital Partners LLP purchased a new position in shares of Bionano Genomics during the 3rd quarter worth approximately $46,000. Price T Rowe Associates Inc. MD grew its stake in shares of Bionano Genomics by 123.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 70,370 shares of the company’s stock valued at $79,000 after buying an additional 38,900 shares in the last quarter. Finally, Cetera Advisors LLC purchased a new stake in Bionano Genomics during the first quarter worth about $163,000. 11.35% of the stock is currently owned by institutional investors and hedge funds.

Bionano Genomics Company Profile

Bionano Genomics, Inc provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA.